Manipal Health closes Rs 9,275 crore IPO subscribed 4.92 times
Manipal Health Enterprises closed its Rs 9,275.22 crore mainboard IPO subscribed 4.92 times, per exchange data; the shares are scheduled to list on the BSE and NSE on 5 August 2026.
The Development
Manipal Health Enterprises Limited, one of India's largest hospital operators, closed its Rs 9,275.22 crore initial public offering on Friday, 31 July 2026, and the mainboard issue was subscribed 4.92 times overall, per exchange bid data at the close. The offer had opened on 29 July, with the anchor-investor book built on 28 July, per the red herring prospectus filed with SEBI. With the three-day bidding window over, the registrar, KFin Technologies, has moved to finalise the basis of allotment, and the shares are scheduled to list on the BSE and NSE on 5 August 2026.
The offer ranks among the larger Indian primary-market issues of 2026. Category-wise, the qualified institutional buyers (QIB) portion was subscribed 8.25 times, the non-institutional investors (NII) category 1.02 times, and the retail segment received bids for about 93% of the shares reserved for it, per the exchange figures reported at the close. At the upper end of the Rs 560 to Rs 590 price band, the fresh-issue-plus-offer-for-sale structure was sized at Rs 9,275.22 crore. The development was surfaced through coverage on the Economic Times IPO desk.
The Company
Founded in 2010, Manipal Health Enterprises operates a network of multi-specialty hospitals, clinics and diagnostic centres offering tertiary and quaternary care across oncology, cardiology, neurology, orthopaedics, organ transplantation and preventive health. As of 31 March 2026 the company operated 49 hospitals with 13,037 licensed beds and 21 clinics, with a workforce exceeding 24,000, including more than 11,000 nurses and 6,300 paramedics, per the offer document and the company's disclosures.
The company discloses revenue from operations of Rs 10,335.75 crore in the financial year ended 31 March 2026, up from Rs 8,242.25 crore in FY2025 and Rs 6,171.63 crore in FY2024, on a restated consolidated basis. Profit for the year was Rs 916.52 crore in FY2026, against Rs 1,081.67 crore in FY2025 and Rs 533.20 crore in FY2024, per the RHP, while EBITDA stood at Rs 2,721.87 crore in FY2026. Net worth was Rs 8,440.92 crore as at 31 March 2026. The RHP also records total borrowings rising to Rs 10,553.43 crore in FY2026 from Rs 4,766.83 crore a year earlier. The promoters named in the RHP include Dr Ranjan Ramdas Pai alongside Manipal Global Health Services, MEMG International Ltd and three overseas investment entities.
The Offer Structure
The offer combines a fresh issue of 13.56 crore equity shares aggregating Rs 8,000 crore with an offer for sale of up to 2,16,13,834 equity shares aggregating Rs 1,275.22 crore, for a total of Rs 9,275.22 crore at the upper band, per the RHP. The company will not receive any proceeds from the offer for sale; those go to the selling shareholders, namely Imperius Healthcare Investments Pte Ltd (up to 1.08 crore shares), Manipal Education and Medical Group India Private Limited (up to 0.68 crore), TPG SG Magazine Pte Ltd (up to 0.23 crore) and Seventy Second Investment Company LLC (up to 0.08 crore).
The stated objects of the fresh issue are the repayment or prepayment of certain borrowings of its material subsidiary Manipal Hospitals Private Limited (Rs 5,552.76 crore), the acquisition of a minority stake in step-down subsidiary Sahyadri Hospitals Private Limited (Rs 574 crore), and general corporate purposes. The book-running lead managers are Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India and J.P. Morgan India, with KFin Technologies as registrar. Readers working through the arithmetic of an allotment can use Oquilia's lumpsum calculator or CAGR calculator, and the /news desk carries prior primary-market coverage.
Risk Factors
The RHP sets out the risks the company was required to disclose, and several concern concentration. The RHP lists geographic concentration first: the company derived 46.40%, 51.55% and 59.98% of revenue from operations from its Karnataka hospitals in FY2026, FY2025 and FY2024 respectively, so disruption there could materially affect results. The company also discloses that it primarily earns revenue from inpatient care, and that an inability to maintain admissions and occupancy rates could weigh on performance.
Among the further risk factors the company discloses is specialty concentration, with 64.30% of gross inpatient revenue in FY2026 coming from a defined group of specialties. The RHP flags that part of the net proceeds will repay non-convertible debentures held by DBS Bank Ltd, deemed an associate of one of the promoters and selling shareholders. The offer document additionally lists exposure to medical-negligence and regulatory claims, risks around integrating acquisitions, and the potential impact of negative publicity on the company's brand.
What Happens Next
With bidding closed on 31 July, the standard mechanics run from allotment forward. The basis of allotment is finalised by the registrar, KFin Technologies, after which allotted shares are credited to demat accounts and blocked funds are released for unsuccessful applicants through the ASBA and UPI process. Applicants can verify their status on the registrar's portal and on the BSE and NSE websites, per the exchange notices.
Per the offer timetable, the shares are scheduled to list on the BSE and NSE on 5 August 2026. The listing price will be set by the exchanges on debut and stated against the Rs 590 upper-band issue price. These are process steps drawn from the record and the announced dates; they describe the mechanics of the issue and not any expectation of demand or price.
FAQ
Should I apply for this IPO?
Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges, and can be read directly before making any decision.
What is the price band and issue size?
Per the RHP, the price band was fixed at Rs 560 to Rs 590 per equity share. The total offer size at the upper band was Rs 9,275.22 crore, comprising a Rs 8,000 crore fresh issue and a Rs 1,275.22 crore offer for sale.
When did the issue open and close?
The anchor-investor book was built on 28 July 2026, and the public subscription window ran from 29 July to 31 July 2026, per the red herring prospectus. The shares are scheduled to list on 5 August 2026.
How was the issue subscribed?
Per exchange data at the close, the issue was subscribed 4.92 times overall, with the QIB portion at 8.25 times, the NII category at 1.02 times, and the retail portion at about 93% of the shares reserved for it.
Where can I read the RHP?
The red herring prospectus is published on SEBI's website under public-issue filings and on the BSE and NSE. It contains the full financial statements, the objects of the issue and the complete risk-factors section.
This report is based on the red herring prospectus filed with SEBI and exchange subscription data reported by the NSE and BSE. It was surfaced via coverage in The Economic Times.